EverHint — Insider Trading & Company News - November 6, 2025

November 6, 2025

Scope: Highlights from today’s Form 4s with emphasis on open-market buys/sells and any 10%-owner moves. Each item includes quick, recent context from company news.

10%-Owner & Control-Level Activity

BPRN — Princeton Bancorp
Who: Martin Tuchman (Director, 10% owner)
What: Buy 2,000 @ $32.25 ($64,500), 11/04
Filing: SEC Form 4 (issuer index)
Link: https://www.sec.gov/Archives/edgar/data/1913971/000119312525268393/0001193125-25-268393-index.htm
Context: Local-bank insider accumulation continues to trickle in the regionals complex. (Investing.com)

NVCT — Nuvectis Pharma
Who: Ron Bentsur (Director, 10% owner; Chair & CEO)
What: Buy 5,000 @ $5.72 ($28,600), 11/05
Filing: SEC Form 4 (issuer index)
Link: https://www.sec.gov/Archives/edgar/data/1875558/000110465925107422/0001104659-25-107422-index.htm
Context: Comes alongside this week’s Q3 update and runway commentary into 3Q-2027. (BioSpace)

ODYS — Odysight.ai
Who: Y.D. More Investments Ltd. (10% owner)
What: Sale 3,550 @ $2.81 ($9,976), 11/05
Filing: SEC Form 4 (issuer index)
Link: https://www.stocktitan.net/sec-filings/ODYS/form-4-odysight-ai-inc-insider-trading-activity-02838be47d8c.html
Context: Another small trim by a major holder; company has been active on the investor-relations circuit this month. (Investing.com)

RVP — Retractable Technologies
Who: Thomas J. Shaw (President & CEO, Director, 10% owner)
What: Buy 7,500 @ $0.826 ($6,195), 11/05
Filing: SEC Form 4 (issuer index)
Link: https://www.stocktitan.net/sec-filings/RVP/form-4-retractable-technologies-inc-insider-trading-activity-788bfe59aac6.html
Context: Insider has been an intermittent buyer; note upcoming earnings window flagged by several outlets. (Stock Titan)

Notable Insider Buys (Open-Market)

RLMD — Relmada Therapeutics

• Maged Shenouda (CFO): Buy 500,000 @ $2.20 ($1.10M), 11/05 → SEC Form 4
• Sergio Traversa (CEO/Director): Buy 272,500 @ $2.20 ($599.5K), 11/05 → SEC Form 4
  Context: Follows Nov 4 announcement of a $100M equity financing; company also highlighted FDA feedback on registrational paths last month. (Relmada Therapeutics, Inc.)

TDUP — ThredUp

• Daniel J. Nova (Director): Buy 65,000 @ $8.0354 ($522.3K), 11/05 → SEC Form 4
  Context: Lands just after Q3 results showing strong ~34% YoY revenue growth. (ir.thredup.com)

MTDR — Matador Resources

• Joseph Wm. Foran (Founder, Chairman & CEO): Buy 3,800 @ $40.21 ($153K), 11/04 → SEC Form 4
  Context: Multiple executives have been adding shares around the post-print dip; coverage today highlighted new insider buys. (Investing.com)

GCBC — Greene County Bancorp

• Tejraj S. Hada (Director): Buys 1,500 @ $22.52 ($33.8K) on 11/05 and 45 @ $22.20 ($999) on 11/04 → SEC Form 4
  Context: Insider activity clusters around the board’s recent quarterly dividend declaration. (TradingView)

Notable Insider Sells (Open-Market)

VICR — Vicor

• Robert Gendron (Corp. VP, Marketing): Sale 5,374 @ $94.00 ($505.2K), 11/05 → SEC Form 4
  Context: Comes two weeks after a strong Q3 beat and rally. (Investing.com)

IDCC — InterDigital

• Rajesh Pankaj (CTO): Sale 1,000 @ $375.31 ($375.3K), 11/05 → SEC Form 4
  Context: Follows this week’s German court injunction win against Disney. (ir.interdigital.com)

HNVR — Hanover Bancorp

• Robert Golden (Director): Sale 5,000 @ $21.2495 ($106.2K), 11/04 → SEC Form 4
  Context: Recent headlines also flagged a $0.10 quarterly dividend payable Nov 20. (MarketBeat)

YUM — Yum! Brands

• Scott Mezvinsky (KFC Division CEO): Sale 273 @ $154.27 ($42.1K), 11/05 → SEC Form 4
  Context: Small one-off sale against a backdrop of recent C-suite changes (CFO → CEO transition effective Oct 1; new CFO named last month). (Reuters)

Quick Take

• Biotech (RLMD, NVCT): Sizeable RLMD C-suite buys after a $100M raise and FDA feedback signal conviction into upcoming milestones; NVCT chair/CEO buy follows a positive funding-runway update—constructive skew. (Relmada Therapeutics, Inc.)
• Energy (MTDR): Founder/CEO add plus other recent exec purchases near cycle lows—positive if accumulation persists. (Investing.com)
• Banks (BPRN, GCBC, HNVR): Mixed tape—director/10% owner buying at BPRN and GCBC vs a HNVR director sale soon after a dividend declaration—neutral/constructive overall for community banks. (Investing.com)
• Semis & Licensing (VICR, IDCC): VICR exec sale into strength after an upside quarter (not thesis-breaking by itself); IDCC sale lands after a legal win—neutral read on both. (Investing.com)

Method: We prioritize open-market Form 4s (codes P and S) and material 10%-owner moves, excluding routine awards, gifts, and tax-withholding entries. Dollar values = reported shares × price in the filings. Dates shown are transaction dates.

Independent research. No hype, no pumps, no paid promotions — just clean, data-driven signals and concise context.